Page last updated: 2024-09-04

bdp 12 and Cognition Disorders

bdp 12 has been researched along with Cognition Disorders in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ballew, N	1
Lynch, G	1
Berry-Kravis, E; Block, SS; Cogswell, J; Cook, E; Decle, P; Guter, S; Hagerman, R; Jardini, T; Johnson, SA; Krause, SE; Lara, R; Leurgans, S; Maino, D; Potanos, K; Salt, J; Weinberg, D; Wuu, J	1
Freudenreich, O; Goff, DC; Green, MF; Johnson, SA; Lamberti, JS; Leon, AC; Manschreck, T; Miller, AL; Patel, J	1

Reviews

1 review(s) available for bdp 12 and Cognition Disorders

Article	Year
Glutamate-based therapeutic approaches: ampakines. Current opinion in pharmacology, 2006, Volume: 6, Issue:1 Topics: Animals; Brain; Cognition Disorders; Dioxoles; Drug Evaluation, Preclinical; Excitatory Amino Acid Agonists; Humans; Memory; Mental Disorders; Nerve Growth Factors; Oxazines; Piperidines; Protein Conformation; Receptors, AMPA	2006

Trials

2 trial(s) available for bdp 12 and Cognition Disorders

Article	Year
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. Journal of child and adolescent psychopharmacology, 2006, Volume: 16, Issue:5 Topics: Adolescent; Adult; Autistic Disorder; Child Behavior Disorders; Cognition Disorders; Dioxoles; Dose-Response Relationship, Drug; Double-Blind Method; Drug Eruptions; Female; Fragile X Syndrome; Humans; Long-Term Potentiation; Male; Neuronal Plasticity; Neuropsychological Tests; Personality Assessment; Piperidines; Receptors, AMPA; Synaptic Transmission; Treatment Outcome	2006
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dioxoles; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Pilot Projects; Piperidines; Psychiatric Status Rating Scales; Psychomotor Performance; Risperidone; Sample Size; Schizophrenia; Schizophrenic Psychology	2008

Article

Year

Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.

Journal of child and adolescent psychopharmacology, 2006, Volume: 16, Issue:5

Topics: Adolescent; Adult; Autistic Disorder; Child Behavior Disorders; Cognition Disorders; Dioxoles; Dose-Response Relationship, Drug; Double-Blind Method; Drug Eruptions; Female; Fragile X Syndrome; Humans; Long-Term Potentiation; Male; Neuronal Plasticity; Neuropsychological Tests; Personality Assessment; Piperidines; Receptors, AMPA; Synaptic Transmission; Treatment Outcome

2006

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:3

Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cognition Disorders; Dioxoles; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Olanzapine; Pilot Projects; Piperidines; Psychiatric Status Rating Scales; Psychomotor Performance; Risperidone; Sample Size; Schizophrenia; Schizophrenic Psychology

2008

Other Studies

1 other study(ies) available for bdp 12 and Cognition Disorders

Article	Year
Cortex Pharmaceuticals, Inc. Maintaining brain function goes a long way. Chemistry & biology, 2003, Volume: 10, Issue:11 Topics: Animals; Brain; Cognition Disorders; Dioxoles; Drug Industry; Humans; Piperidines; Receptors, AMPA; Schizophrenia	2003